Page URL: https://www.bionews.org.uk/page_94048

Just five patients but gene therapy leukaemia trial yields positive results

25 March 2013
Appeared in BioNews 698

Early results of an experimental gene therapy against an aggressive form of leukaemia have been hailed by researchers as showing 'life-saving potential'.

The study, published last week in the journal Translational Medicine, focussed on the treatment of patients with acute lymphoblastic leukaemia (ALL) - an aggressive, fast-growing cancer of a subset of white blood cells known as 'B cells'.

In the trial, five adult patients' immune cells were removed, genetically modified and reinserted back into their bodies to target the tumour. As a result of this experimental treatment, all of the patients' tumours were seen to have significantly shrunk and their cancer sent into remission, demonstrating the therapeutic potential of such 'immunotherapies' in people with cancer.

The team harnessed the normal functioning of a type of immune cell called T cells to achieve this effect. T cells protect the body by fighting infection from certain viruses and cancers. They detect molecules studded on the outside of these infectious agents to 'home in' on them, secreting chemicals called cytokines to destroy the intruders, and so rid the body of infection.

In normal functioning, T cells will only respond to agents displaying these specific molecules, explaining why they do not attack all cancer or viruses, or indeed the body's own cells. However, by modifying the genetics of these cells, Dr Michel Sadelain of Memorial Sloan-Kettering Cancer Center, USA and his team re-trained their patients' T cells to target any cells expressing one particular molecule, called CD19. As CD19 is expressed by leukaemia cells, the modified T cells target and kill them, clearing the leukaemia from the body in the process.

'The T cells are living drugs', Dr Sadelain explained. 'They see the CD19, they kill the cancer cells, and they persist in the body'.

Despite being in the earliest stages of development, these results offer hope for the future treatment of patients with ALL. When, as is most common, ALL occurs in children prognosis is good, with current treatments capable of curing an estimated 80-90 percent of cases. However, this efficacy drops dramatically to below 30 percent when the disease is seen in adults, leading to what Dr Sadelain describes as 'a dismal prognosis'.

The results of this study show that, in such cases, cancers could be driven quickly into remission, crucially allowing patients to become eligible for bone marrow transplants and therefore dramatically improving their prognosis.

The therapy is, however, not without side-effects. Following treatment, two of the patients in the trial developed a condition termed 'cytokine storm', where the massive overproduction of cytokines (a group of chemicals cells use to communicate) by the genetically-invigorated T cells led to their blood pressure plummeting and fevers spiking. Additionally, as the target-molecule CD19 is expressed by both cancerous and healthy white blood cells, T cells are unable to discriminate between the two, leading to all of the body's B cells being destroyed. Patients without B cells are more susceptible to infection.

Typically, pharmaceutical companies have been wary of such therapies, not least due to the difficulties in obtaining regulatory approval. Meanwhile, the research team is currently pursuing a larger trial of over 50 participants to further study the effects of this experimental treatment.

SOURCES & REFERENCES
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Science Translational Medicine |  20 March 2013
Cell-Based Immune Therapy Shows Promise in Leukemia Patients
Memorial Sloan-Kettering Cancer Center (press release) |  20 March 2013
Cell Therapy Shows Promise for Acute Type of Leukemia
New York Times |  20 March 2013
Engineered immune cells battle acute leukaemia
Nature News |  20 March 2013
Immune-system therapy shows promise in adults with leukemia
Reuters |  20 March 2013
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
9 November 2015 - by Lone Hørlyck 
An experimental cell-based treatment using gene editing, previously only tested on mice, has successfully reversed advanced leukaemia in a one-year-old girl...
2 March 2015 - by Dr Linda Wijlaars 
This well-timed Panorama documentary details how innovative treatments are being developed at the Institute of Cancer Research and trialled at the Royal Marsden...

24 February 2014 - by Chris Hardy 
Researchers trialling a gene therapy-based treatment for leukemia have said the early results go beyond anything they could have thought of in their 'wildest dreams'...
15 July 2013 - by Dr Nicola Davis 
A clinical trial of a gene therapy to treat children with two types of severe genetic disease has shown early signs of success...
15 April 2013 - by Dr Katie Howe 
Genome analysis of identical twins with childhood leukaemia has helped pinpoint genetic mutations which may kick-start the disease in the mother's womb...
17 December 2012 - by Joseph Jebelli 
A seven-year-old girl with a highly aggressive form of leukaemia may have been 'cured' by an experimental therapy that harnesses the body's immune system to seek out and destroy the disease....
12 November 2012 - by Dr Daniel Grimes 
A biotechnology company has come under fire after reporting success of its 'life-saving' stem cell based therapies ahead of a major stock sale, which occurred before investors became aware of news that a patient who had received its treatment had died....
5 March 2012 - by Ayesha Jadoon 
Early trials in patients with chronic granulomatous disorder (x-CGD), a recessive X-linked condition that affects the immune system, have shown signs of success following the use of gene therapy. The observed boost in immunity of those undergoing treatment was only temporary, however, and the faulty gene causing x-CGD was not corrected permanently....
4 April 2011 - by Maren Urner 
Researchers from the Wellcome Trust Sanger Institute have identified three different genetic mutations linked to acute myeloid leukaemia (AML), a cancer that is characterised by a rapid increase in abnormal white blood cells in the bone marrow....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.